Share

March 2018; 5 (2) Clinical/Scientific NotesOpen Access

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis

Andreas F. Hottinger, Rita de Micheli, Vanessa Guido, Alexandra Karampera, Patric Hagmann, Renaud Du Pasquier
First published January 11, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000439
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1056

Share

Article Information

vol. 5 no. 2 e439
DOI: 
https://doi.org/10.1212/NXI.0000000000000439
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 31, 2017
  • Accepted in final form November 13, 2017
  • First Published January 11, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Andreas F. Hottinger, MD, PhD,
    2. Rita de Micheli, MD*,
    3. Vanessa Guido, MD*,
    4. Alexandra Karampera, MD*,
    5. Patric Hagmann, MD, PhD* and
    6. Renaud Du Pasquier, MD
  1. Andreas F. Hottinger, MD, PhD,
    2. Scientific Advisory Boards:

    1. Novocure, paid to the institution BMS, paid to the institution Servier, paid to the institution

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novovure, travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Novocure, paid to the institution

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rita de Micheli, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Vanessa Guido, MD*,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Alexandra Karampera, MD*,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Patric Hagmann, MD, PhD* and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Renaud Du Pasquier, MD
    7. Scientific Advisory Boards:

    1. Biogen, Genzyme, Merck, Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Sanofi, Genzyme, Roche

    Editorial Boards:

    1. Editorial boards of Journal of Neurovirology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swiss National Foundation 320030-159997; Swiss Society for Multiple Sclerosis; Novartis Investigator-initiated trial

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Clinical Neurosciences (A.F.H., V.G., A.K., R.D.P.), Department of Oncology (A.F.H., R.d.M.), and Department of Radiology (P.H.), CHUV University Hospital & University of Lausanne, Switzerland.
  1. Correspondence
    Dr. Hottinger Andreas.hottinger{at}gmail.com
View Full Text

Article usage

Article usage: January 2018 to March 2023

AbstractFullPdfSource
Jan 2018021942Highwire
Feb 2018044933Highwire
Mar 2018027770Highwire
Apr 2018018734Highwire
May 2018084129Highwire
Jun 2018015722Highwire
Jul 201805610Highwire
Aug 201818922Highwire
Sep 201807219Highwire
Oct 201809426Highwire
Nov 2018015527Highwire
Dec 2018013918Highwire
Jan 2019210614Highwire
Feb 201999817Highwire
Mar 201926820Highwire
Apr 20193496Highwire
May 201966820Highwire
Jun 201913818Highwire
Jul 201974313Highwire
Aug 2019813623Highwire
Sep 201963428Highwire
Oct 201986220Highwire
Nov 201954917Highwire
Dec 201957711Highwire
Jan 202085014Highwire
Feb 202055124Highwire
Mar 202042517Highwire
Apr 20207317Highwire
May 202044417Highwire
Jun 202064319Highwire
Jul 20202335Highwire
Aug 202035411Highwire
Sep 20201012315Highwire
Oct 20202469Highwire
Nov 202093414Highwire
Dec 20207339Highwire
Jan 202162212Highwire
Feb 202122710Highwire
Mar 20213448Highwire
Apr 202152917Highwire
May 202126613Highwire
Jun 20212506Highwire
Jul 202154815Highwire
Aug 202135912Highwire
Sep 202153413Highwire
Oct 202142928Highwire
Nov 202142321Highwire
Dec 20211359Highwire
Jan 20223227Highwire
Feb 202262311Highwire
Mar 202255013Highwire
Apr 20222357Highwire
May 202239414Highwire
Jun 20225268Highwire
Jul 20225213Highwire
Aug 20226358Highwire
Sep 202254413Highwire
Oct 202244414Highwire
Nov 2022117429Highwire
Dec 202262812Highwire
Jan 2023205818Highwire
Feb 2023113015Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles